Actively Recruiting
Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)
Led by Chonnam National University Hospital · Updated on 2026-04-27
1014
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD. Therefore, we planned to perform prospective, open-label, randomized trial to evaluate the efficacy and safety of immediate complete revascularization (percutaneous coronary intervention \[PCI\] for both infarct-related artery \[IRA\] and non-IRA during index PCI) compared to staged PCI strategy of non-IRA (PCI for IRA followed by non-IRA PCI after several days). PCI procedure at non-IRA with diameter stenosis between 50 and 69% should be conducted with the aid of fractional flow reserve (FFR), and non-IRA with diameter stenosis ≥ 70% will be revascularized without FFR.
CONDITIONS
Official Title
Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 19 years or older
- Diagnosed with non-ST-segment elevation myocardial infarction (NSTEMI) confirmed by chest pain or equivalent ischemic symptoms with at least one of the following: occurs at rest lasting more than 10 minutes, new severe onset within 4-6 weeks, or worsening pattern
- Elevated cardiac biomarkers with high-sensitivity troponin values at or above 99% threshold
- No significant ST-segment elevation on ECG or new left bundle branch block
- Undergoing percutaneous coronary intervention (PCI) within 72 hours of symptom onset
- Multivessel disease involving non-infarct arteries with at least 2.5 mm diameter and 50% or greater stenosis
- Agreement by patient or protector to participate and understand study risks
You will not qualify if you...
- Cardiogenic shock at initial presentation or after infarct-related artery treatment
- TIMI flow grade 2 or less in non-infarct-related arteries
- Severe complications during procedure such as no-reflow or coronary perforation preventing study participation
- Non-infarct artery lesions deemed unsuitable for PCI
- Presence of chronic total occlusion in non-infarct arteries
- History of allergic reaction to contrast agents
- Pregnancy or breastfeeding
- Life expectancy less than 1 year
- Severe heart valve disease
- Previous or planned coronary artery bypass graft surgery
- Received fibrinolysis treatment before hospital admission
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chonnam National University Hospital
Gwangju, South Korea
Actively Recruiting
Research Team
M
Min Chul Kim, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here